한글목차

면역치료제는 면역반응을 강화하거나 면역체계의 조절 메커니즘을 조절하여 질병을 유발하는 물질과 세포를 효과적으로 표적화하여 제거할 수 있도록 고안된 약물입니다.

면역치료제 시장 규모는 2024년 2,853억 달러에서 2029년 5,806억 달러로 연평균 15.3% 성장할 것으로 예상됩니다. 이러한 성장은 항체 공학의 기술 발전, 임상 암 치료에서 항체 치료에 대한 수요 증가, 개인 맞춤형 의약품 및 표적치료제에 대한 선호도 증가 등에 기인합니다. 그러나 시장은 항체 치료제 개발에 따른 복잡성 등의 도전과제에 직면해 있습니다.

유형별로는 항체의약품, 억제제, 인터페론 및 인터류킨, 암 백신, 기타 면역치료제(온콜로바이러스치료제, T세포 치료제 등)로 나뉩니다. 항체 의약품이 큰 비중을 차지하고 있습니다. 암 발병률 증가, 생물학적 요법 채택 확대, 연구개발 투자 확대, 정부 지원 정책 등이 시장 성장을 촉진할 것으로 예상됩니다.

면역치료제 시장은 용도별로 암, 자가면역질환 및 염증성 질환, 혈액학, 골학, 신경학, 안과, 피부과, 심혈관계 질환을 포함한 기타 용도로 분류되며, 2023년에는 암이 가장 큰 시장 점유율을 차지했습니다. 암 발병률 증가, 생물학적 치료법 채택 증가, R&D 투자 대폭 증가, 유리한 정부 정책 등이 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 면역치료제 분야의 기업들은 새로운 치료법 개발, 전략적 공동연구, 암의 면역치료법 개발을 위한 임상연구에 대한 투자 강화를 통해 혁신성을 입증하고 있습니다. 이러한 노력은 암과 싸우는 면역체계의 능력을 향상시켜 새로운 희망과 환자 치료 결과를 개선하는 것을 목표로 하고 있습니다.

투여 경로에 따라 면역치료제 시장은 크게 정맥, 피하, 기타 투여 경로(유리체강 내, 근육 내)로 나뉘며, 2023년에는 정맥 투여가 면역치료제 시장에서 가장 큰 점유율을 차지했습니다. 또한, 이 부문은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이러한 큰 점유율과 높은 성장률은 혈류에 직접 투여하기 때문에 암, 자가면역질환 등 여러 질환에 대해 신속하고 안정적인 치료 효과가 있어 정맥 투여 경로에 대한 선호도가 높아졌기 때문입니다.

이 보고서는 세계 면역치료제 시장을 조사하여 유형별, 용도별, 투여 경로별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 정리한 보고서입니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 소개
• 시장 역학
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 밸류체인 분석
• 공급망 분석
• 가격 분석
• 생태계 분석
• 특허 분석
• 기술 분석
• 투자와 자금 조달 시나리오
• 2024-2025년의 주요 회의와 이벤트
• 사례 연구 분석
• 규제 상황

제6장 면역치료제 시장(유형별)

• 소개
• 항체 의약품
• 억제제
• 인터페론과 인터류킨
• 암 백신
• 기타

제7장 면역치료제 시장(용도별)

• 소개
• 암
• 자가면역질환 및 염증성 질환
• 혈액
• 골
• 신경
• 기타

제8장 면역치료제 시장(투여 경로별)

• 소개
• 정맥내 투여
• 피하 투여
• 기타

제9장 면역치료제 시장(최종사용자별)

• 소개
• 병원
• 장기간병 시설
• 기타

제10장 면역치료제 시장(지역별)

• 소개
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제11장 경쟁 상황

• 소개
• 주요 진출 기업 전략/비책
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 진출 기업, 2023년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
• 기업 평가와 재무 지표
• 브랜드/제품 비교
• 경쟁 시나리오

제12장 기업 개요

• 주요 진출 기업
  • MERCK & CO., INC.
  • JOHNSON & JOHNSON SERVICES, INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • ASTRAZENECA
  • PFIZER INC.
  • AMGEN INC.
  • NOVARTIS AG
  • ELI LILLY AND COMPANY
  • SANOFI
  • BRISTOL-MYERS SQUIBB COMPANY
  • GILEAD SCIENCES, INC.
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ABBVIE INC.
  • GSK PLC
• 기타 기업
  • IMMUNOCORE HOLDINGS PLC
  • ASTELLAS PHARMA INC.
  • GENMAB A/S
  • MACROGENICS, INC.
  • FERRING BV
  • Y-MABS THERAPEUTICS, INC.
  • BIOGEN
  • KYOWA KIRIN CO., LTD.
  • SWEDISH ORPHAN BIOVITRUM AB
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH

제13장 부록

영문목차

Immunotherapy drugs are designed to enhance the immune response or modulate the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cellsThe immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, reflecting a compound annual growth rate (CAGR) of 15.3%. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies. However, the market faces challenges such as the complexities involved in developing antibody therapeutics.

The Antibody drugs segment maintains major market share in the forecast period.

Based on type, the immunotherapy drugs market is divided into antibody drugs, inhibitor drugs, interferons & interleukins, cancer vaccines, and other immunotherapy drugs, which include oncolytic virus therapy and t-cell therapy. Antibody drugs hold the major market share. Increasing cancer incidence, the growing adoption of biological therapies, heightened investment in R&D, and supportive government policies are anticipated to propel market growth.

The Cancer segment is anticipated to dominate Immunotherapy Drugs Market through 2023-2029.

Based on applications, the immunotherapy drugs market is divided into cancer, autoimmune & inflammatory diseases, hematology, osteology, neurology, and other applications, including ophthalmology, dermatology, and cardiovascular diseases. Cancer commanded the largest market share in 2023. Elevated cancer rates, increased adoption of biological therapies, substantial R&D investment, and favorable government policies are expected to drive market growth during the forecast period. Companies in the immunotherapy drugs sector are exemplifying innovation through the development of new therapies, strategic collaborations, and enhanced spending on clinical research to explore immunotherapy treatments for cancer. These efforts aim to boost the immune system's capability to fight cancer, offering new hope and improved patient outcomes.

The Intravenous Route segment is anticipated to grow at the fastest pace throughout the forecast period.

Based on the route of administration, the immunotherapy drugs market is broadly segmented into intravenous, subcutaneous, and other routes of administration (intravitreal and intramuscular). In 2023, the intravenous route of administration segment accounted for the largest share of the immunotherapy drugs market. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate are attributed to the growing preference for intravenous routes owing to its direct delivery into the bloodstream, ensuring rapid and consistent therapeutic effects for several conditions, including cancer and autoimmune diseases.

Hospitals segment generated the highest revenue in 2024 in the market.

Based on end users, the immunotherapy drugs market is broadly segmented into hospitals, long-term care facilities, and other end users (specialty care centers). In 2023, the hospitals segment commanded the largest share of the immunotherapy drugs market. Hospitals extensively use mAbs for their targeted therapy, rapid diagnostic applications, and efficacy in treating several disease indications, including cancer, autoimmune disorders, and infectious diseases.

The North America accounted for the largest share in the immunotherapy drugs market.

In 2023, North America accounted for the largest share of the global immunotherapy drugs market. The growth in the North American market can be attributed to rising immunotherapy research, the expansion of the healthcare sector, growing cancer prevalence, and the increasing approval and adoption of immunotherapy drugs for treating cancer and other chronic diseases. North America has witnessed significant growth in medical research advancements, growing clinical trials, and the developing biopharmaceutical industry. With increased research-driven activities and a high prevalence of cancer and chronic diseases, the demand for immunotherapies in North America is expected to rise significantly.

Breakdown of supply-side primary interviews by company type, designation, and region:

• By Respondent: Supply Side (70%), Demand side (30%)
• By Designation: C-level (55%), Director-level (20%), and Others (25%)
• By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report

• Merck & Co., Inc. (US)
• Johnson & Johnson Services, Inc. (US)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Pfizer Inc. (US)
• AstraZeneca (UK)
• Novartis AG (Switzerland)
• Amgen Inc. (US)
• Gilead Sciences, Inc. (UK)
• Bristol-Myers Squibb Company (US)
• Eli Lilly and Company (US)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd (Israel)
• GSK PLC (US)
• Abbvie Inc. (US)

Research Coverage

This report studies the Immunotherapy Drugs market based on type, application, route of administration, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Immunotherapy Drugs market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

• Market Drivers: The key factors driving the overall market growth are technological advancements in antibody engineering, Increased demand for antibody therapies in clinical cancer treatment, and Growing demand for personalized medicines and targeted therapies
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the Immunotherapy Drugs market.
• Market Penetration: Comprehensive information on Immunotherapy Drugs offered by the top 15 players in the market. The report analyzes the Immunotherapy Drugs market by Type, Application, Route of Administration, End User and Region
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of Immunotherapy Drugs across key geographic regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Immunotherapy Drugs market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Immunotherapy Drugs market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS COVERED
  • 1.3.2 REGIONS COVERED
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
  • 1.3.5 UNITS CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES
  • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 IMPACT OF ECONOMIC RECESSION ON IMMUNOTHERAPY DRUGS MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW
• 4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE AND COUNTRY (2023)
• 4.3 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Technological advancements in antibody engineering
    • 5.2.1.2 Increasing demand for antibody therapeutics in clinical cancer treatment
    • 5.2.1.3 Growing demand for personalized medicines and targeted therapies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulatory approval process for immunotherapy drugs
    • 5.2.2.2 High cost of monoclonal antibody therapeutics
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising number of approvals for CAR T-cell therapies
    • 5.2.3.2 Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutes
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complexities in development of antibody therapeutics
• 5.3 PORTER'S FIVE FORCES ANALYSIS
  • 5.3.1 THREAT OF NEW ENTRANTS
  • 5.3.2 THREAT OF SUBSTITUTES
  • 5.3.3 BARGAINING POWER OF SUPPLIERS
  • 5.3.4 BARGAINING POWER OF BUYERS
  • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.4 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.4.2 KEY BUYING CRITERIA
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER
  • 5.7.2 AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021-2023
  • 5.7.3 INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION
  • 5.7.4 INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
• 5.9 PATENT ANALYSIS
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Gene editing
    • 5.10.1.2 High-throughput screening
    • 5.10.1.3 Next-generation sequencing
  • 5.10.2 COMPLEMENTARY TECHNOLOGIES
    • 5.10.2.1 Nanotechnology
    • 5.10.2.2 Artificial intelligence
• 5.11 INVESTMENT & FUNDING SCENARIO
  • 5.11.1 MAJOR INVESTMENTS AND FUNDING
  • 5.11.2 OTHER INVESTMENTS AND FUNDING
• 5.12 KEY CONFERENCES & EVENTS, 2024-2025
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: EFFICACY OF KEYTRUDA IN CANCER TREATMENT
  • 5.13.2 CASE STUDY 2: EFFECTIVE USE OF LYNPARZA IN PROSTATE CANCER TREATMENT
  • 5.13.3 CASE STUDY 3: CLINICAL TRIALS OF ORPATHYS (SAVOLITINIB)
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY ANALYSIS
    • 5.14.1.1 North America
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
      • 5.14.1.2.1 Germany
      • 5.14.1.2.2 UK
      • 5.14.1.2.3 Rest of Europe
    • 5.14.1.3 Asia Pacific
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 South Korea
      • 5.14.1.3.4 Australia
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.14.2.1 North America
    • 5.14.2.2 Europe
    • 5.14.2.3 Asia Pacific
    • 5.14.2.4 Latin America
    • 5.14.2.5 Middle East & Africa

6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 ANTIBODY DRUGS
  • 6.2.1 ROBUST CLINICAL PIPELINE OF ANTIBODY THERAPEUTICS TO SUPPORT MARKET GROWTH
• 6.3 INHIBITOR DRUGS
  • 6.3.1 INCREASED FOCUS ON DEVELOPMENT OF TARGET MEDICINES AND COMBINATION THERAPIES TO FUEL MARKET GROWTH
• 6.4 INTERFERONS & INTERLEUKINS
  • 6.4.1 INCREASED FOCUS ON R&D AND DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO AUGMENT MARKET GROWTH
• 6.5 CANCER VACCINES
  • 6.5.1 RISING FOCUS ON RESEARCH ACTIVITIES AND CLINICAL TRIALS TO SPUR MARKET GROWTH
• 6.6 OTHER IMMUNOTHERAPY DRUGS

7 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 CANCER
  • 7.2.1 LARGE R&D SPENDING AND HIGH GOVERNMENT INVESTMENTS TO DRIVE MARKET
• 7.3 AUTOIMMUNE & INFLAMMATORY DISEASES
  • 7.3.1 ADVANCEMENTS IN MOLECULAR ENGINEERING AND INTRODUCTION OF BIOLOGICAL DRUGS TO PROPEL MARKET GROWTH
• 7.4 HEMATOLOGY
  • 7.4.1 INCREASED R&D IN CELL-BASED THERAPIES, MONOCLONAL ANTIBODIES, AND IMMUNE CHECKPOINT INHIBITORS TO AID MARKET GROWTH
• 7.5 OSTEOLOGY
  • 7.5.1 GROWING INCIDENCE OF OSTEOPOROSIS-RELATED FRACTURES TO DRIVE MARKET
• 7.6 NEUROLOGY
  • 7.6.1 ADVANCEMENTS IN NEUROLOGICAL DRUG DEVELOPMENT TO BOOST MARKET GROWTH
• 7.7 OTHER APPLICATIONS

8 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 INTRODUCTION
• 8.2 INTRAVENOUS ROUTE OF ADMINISTRATION
  • 8.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE TO PROPEL MARKET GROWTH
• 8.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • 8.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO AID MARKET GROWTH
• 8.4 OTHER ROUTES OF ADMINISTRATION

9 IMMUNOTHERAPY DRUGS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH
• 9.3 LONG-TERM CARE FACILITIES
  • 9.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
• 9.4 OTHER END USERS

10 IMMUNOTHERAPY DRUGS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 NORTH AMERICA: RECESSION IMPACT
  • 10.2.2 US
    • 10.2.2.1 US to dominate North American immunotherapy drugs market during forecast period
  • 10.2.3 CANADA
    • 10.2.3.1 Rising government initiatives for research on regenerative medicine to drive market
• 10.3 EUROPE
  • 10.3.1 EUROPE: RECESSION IMPACT
  • 10.3.2 GERMANY
    • 10.3.2.1 Increasing investments in healthcare research to fuel market growth
  • 10.3.3 UK
    • 10.3.3.1 Favorable government initiatives and high R&D investments to propel market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Increasing adoption of immunotherapy drugs and growing focus on healthcare R&D to augment market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Strong focus on clinical research and stringent government regulations to propel market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Favorable government initiatives to spur market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 10.4.2 CHINA
    • 10.4.2.1 Less-stringent regulatory framework and high incidence of cancer to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Rising geriatric population and increasing government support to augment market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing prevalence of cancer and rising government healthcare investments to aid market growth
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Strong biopharmaceutical sector and favorable government initiatives to support market growth
  • 10.4.6 AUSTRALIA
    • 10.4.6.1 High prevalence of cancer and increased expenditure on health services to propel market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 LATIN AMERICA: RECESSION IMPACT
  • 10.5.2 BRAZIL
    • 10.5.2.1 Developed healthcare infrastructure and unified public health system to fuel market growth
  • 10.5.3 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MIDDLE EAST: RECESSION IMPACT
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Saudi Arabia
      • 10.6.2.1.1 Increasing focus on R&D and growing government support to spur market growth
    • 10.6.2.2 UAE
      • 10.6.2.2.1 Technological advancements and increased government focus on healthcare to support market growth
    • 10.6.2.3 Rest of GCC Countries
  • 10.6.3 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 INCREASING HEALTHCARE FUNDING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
  • 10.7.2 AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Type footprint
    • 11.5.5.3 Application footprint
    • 11.5.5.4 Route of administration footprint
    • 11.5.5.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 MERCK & CO., INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Services/Solutions offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product approvals
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 JOHNSON & JOHNSON SERVICES, INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Services/Solutions offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product approvals
      • 12.1.2.3.2 Deals
      • 12.1.2.3.3 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Services/Solutions offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 ASTRAZENECA
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Services/Solutions offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product approvals
      • 12.1.4.3.2 Deals
      • 12.1.4.3.3 Expansions
  • 12.1.5 PFIZER INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Services/Solutions offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product approvals
      • 12.1.5.3.2 Deals
  • 12.1.6 AMGEN INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Services/Solutions offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product approvals
      • 12.1.6.3.2 Expansions
  • 12.1.7 NOVARTIS AG
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Services/Solutions offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product approvals
      • 12.1.7.3.2 Deals
  • 12.1.8 ELI LILLY AND COMPANY
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Services/Solutions offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product approvals
      • 12.1.8.3.2 Deals
  • 12.1.9 SANOFI
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Services/Solutions offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product approvals
      • 12.1.9.3.2 Deals
  • 12.1.10 BRISTOL-MYERS SQUIBB COMPANY
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Services/Solutions offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product approvals
      • 12.1.10.3.2 Deals
  • 12.1.11 GILEAD SCIENCES, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products/Services/Solutions offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product approvals
      • 12.1.11.3.2 Deals
      • 12.1.11.3.3 Other developments
  • 12.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products/Services/Solutions offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product approvals
      • 12.1.12.3.2 Deals
  • 12.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products/Services/Solutions offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Deals
  • 12.1.14 ABBVIE INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products/Services/Solutions offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product approvals
      • 12.1.14.3.2 Deals
  • 12.1.15 GSK PLC
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products/Services/Solutions offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Product approvals
      • 12.1.15.3.2 Deals
      • 12.1.15.3.3 Other developments
• 12.2 OTHER PLAYERS
  • 12.2.1 IMMUNOCORE HOLDINGS PLC
  • 12.2.2 ASTELLAS PHARMA INC.
  • 12.2.3 GENMAB A/S
  • 12.2.4 MACROGENICS, INC.
  • 12.2.5 FERRING BV
  • 12.2.6 Y-MABS THERAPEUTICS, INC.
  • 12.2.7 BIOGEN
  • 12.2.8 KYOWA KIRIN CO., LTD.
  • 12.2.9 SWEDISH ORPHAN BIOVITRUM AB
  • 12.2.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS